Does body weight influence the response to intravenous tissue plasminogen activator in stroke patients?

Cerebrovascular Diseases

Volumn 27, Issue 1, 2009, Pages 84-90

  Lou, Min ^a   Selim, Magdy ^b,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Clinical outcome; Ischemic stroke; Tissue plasminogen activator; Weight

Indexed keywords

PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STROKE PATIENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; BODY WEIGHT; BRAIN ISCHEMIA; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 56449129021     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000175766     Document Type: Article

References (26)

1. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF; American Heart Association/American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-1711.
2. Levy D, Brott T, Haley EC Jr, Marler J, Sheppard G, Barsan W, Broderick J: Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994;25:291-297.
3. Brott T, Haley EC Jr, Levy D, Barsan W, Broderick J, Sheppard G, Spilker J, Kongable G, Massey S, Reed R, Marler J: Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;3:632-640.
4. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR: Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-645.
5. Skurk T, Hauner H: Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004;28:1357-1364.
6. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, Wilson PW, Levy D, Muller JE, Tofler GH: Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004;91:683-689.
7. Samad F, Loskutoff DJ: Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996;2:568-582.
8. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
9. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28:2109-2118.
10. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T: Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999;340:1781-1787.
11. The NINDS t-PA Stroke Trial Study Group: Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119-2125.
12. Frankel M, Morgenstern LB, Kwiatkowski T, Lu M, Tilley BC, Broderick JP, Libman R, Levine SR, Brott T; NINDS rt-PA Stroke Study Group: Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology 2000;55:952-959.
13. Johnston KC, Connors AF Jr, Wagner DP, Haley EC Jr: Risk adjustment effect on stroke clinical trials. Stroke 2004;35:e43-e45.
14. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.
15. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP: Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke 2005;36:62-65.
16. Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Anderson L, Collen D: Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator: correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. Circulation 1989;80:1222-1230.
17. Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, Arner P: Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998;41:65-71.
18. Crandall DL, Quinet EM, Morgan GA, Busler DE, McHendry-Rinde B, Kral JG: Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes. J Clin Endocrinol Metab 1999;84:3222-3227.
19. Chandler W, Alessi M, Aillaud M, Henderson P, Vague P, Juhan-Vague I: Clearance of TPA and TPA/PAI-1 complex. Circulation 1997;96:761-768.
20. Nagai N, Van Hoef B, Lijnen HR: Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice. J Thromb Haemost 2007;5:1726-1731.
21. WHO: Physical status: the use and interpretation of anthropometry. WHO Technical Report Series. Geneva, World Health Organization, 1995.
22. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W: The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 2006;37:2957-2962.
23. Lansberg MG, Albers GW, Wijman CA: Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007;24:1-10.
24. Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM: Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999;84:4097-4105.
25. Skurk T, Lee YM, Hauner H: Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 2001;37:1336-1340.
26. Kain K, Young J, Bamford J, Bavington J, Grant PJ, Catto AJ: Determinants of plasminogen activator inhibitor-1 in South Asians with ischaemic stroke. Cerebrovasc Dis 2002;14:77-83.